CFM
MYGN icon

Catalyst Funds Management’s Myriad Genetics MYGN Stock Holding History

Catalyst Funds Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,980
Closed -$153K – 801
2026
Q1 		$153K Buy
+33,980
New +$177K 0.03% 471
2024
Q3 		– Sell
-3,200
Closed -$78.3K – 1499
2024
Q2 		$78.3K Buy
+3,200
New +$70.2K 0.02% 338

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Catalyst Funds Management's MYGN Position: Q2 2026 in Review

Catalyst Funds Management sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 33,980 shares — an estimated $153K sold.

Catalyst Funds Management first reported a position in MYGN in Q2 2024 and held it in 2 quarters. The position peaked at $153K in Q1 2026. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Catalyst Funds Management reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 33,980 Myriad Genetics shares in Q2 2026, an estimated $153K.
  • Catalyst Funds Management first reported a position in Myriad Genetics in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Myriad Genetics position peaked at $153K in Q1 2026.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.